(ZP1848) improves short bowel syndrome patients' ability to absorb nutrients from food, according to a Phase 2 clinical trial.
The condition, also known as SBS, occurs when part of the small intestine is missing. Its hallmark is patients being unable to absorb enough nutrients into their body.
It usually results from surgery to deal with Crohn's disease, ischemia or radiation damage. Ischemia is an insufficient supply of blood to an organ, usually because of a blocked artery.
SBS is a life-threatening chronic disease. Those with severe cases can become dependent on daily parenteral support, or being fed intravenously rather than through their digestive system.
Since parenteral support requires tubes and pumps, drugs that are able to reduce the need for IV feeding can improve patients’ quality of life.
Glepaglutide mimics glucagon like peptide 2 (GLP-2), a hormone that the small intestine produces. Because GLP-2 promotes intestinal growth and regeneration, scientists are trying to develop therapies for gastrointestinal diseases around it.
Researchers decided to evaluate the effectiveness, safety and tolerability of three doses of glepaglutide in adults with SBS. The highest dose was 10 times larger than the middle dose and 100 times larger than the smallest.
Sixteen patients completed the trial (NCT02690025
). Each received two doses. The first one was followed by a four-week break and then another dose.
The study's primary objective was to see whether glepaglutide would i